Induction of cytotoxic T-cell response against hepatitis C virus structural antigens using a defective recombinant adenovirus by Bruña-Romero, O. (Oscar) et al.
Induction of Cytotoxic T-Cell Response Against Hepatitis C
Virus Structural Antigens Using a Defective
Recombinant Adenovirus
OSCAR BRUN˜A-ROMERO,1 JUAN JOSE´ LASARTE,1 GAVIN WILKINSON,2 KEN GRACE,3
BERWYN CLARKE,3 FRANCISCO BORRA´S-CUESTA,1 AND JESU´S PRIETO1
the development of new therapeutic methods are importantA replication-defective recombinant adenovirus (RAd),
goals for the future.RAdCMV-CE1, containing core and E1 genes of hepatitis
Cytotoxic T lymphocytes (CTL) have been shown to play aC virus (HCV) was constructed. RAdCMV-CE1 was able
major role in the control of many viral diseases.8-15 HCV infec-to express core and E1 proteins both in mice and human
tion has a strong tendency to chronicity suggesting that thecells. Immunization of BALB/c mice with RAdCMV-CE1
CTL reaction against HCV antigens is poor or ineffective.induced a specific cytotoxic T-cell response against the
Thus, the characterization of CTL epitopes from HCV pro-two HCV proteins. This response was characterized us-
teins as well as the development of efficient ways of inducinging a panel of 60 synthetic 14- or 15-mer overlapping pep-
CTL in vivo are important steps toward prevention and/ortides (10 amino-acid overlap) spanning the entire se-
treatment of HCV infection.quence of these proteins. Five main epitopes were found
To induce in vivo CTL against viral antigens, the use ofin the core protein, four of which had been previously
recombinant viral vectors constitutes an attractive strategy.described either in mice or humans. One single novel
These vectors express recombinant proteins inside the cell,epitope was found in E1. Fine mapping of this E1 deter-
allowing endogenously synthesized antigens to be processedminant, showed that octamer GHRMAWDM is the mini-
in a nonendosomal compartment and the derived peptides ofmal epitope recognized by cytotoxic T lymphocytes
8-10 residues to be transported to the lumen of endoplasmic(CTL). The cytotoxic T-cell response was H-2d restricted,
reticulum where they bind to class-I major histocompatibilitylasted for at least 100 days, and was mediated by T cells
complex molecules for presentation to CD8/ CTL at the cellwith the classic CD40CD8/phenotype. This work demon-
membrane. In fact, previous studies have shown that thestrates that replication-defective recombinant adenovi-
expression of HCV antigens, using recombinant vacciniaruses can efficiently express HCV proteins and are able
virus, is an efficient means to induce specific CTL into induce an in vivo cytotoxic T-cell response against a
mice.16-18 While replication-competent vaccinia recombinantsdiversity of epitopes from HCV antigens. These vectors
entail substantial risks in men,19 replication-deficient adeno-should be taken into consideration in the design of vac-
viruses do not appear to be hazardous for humans.20 Thesecines and also as a means to stimulate specific T-cell re-
recombinant viruses are able to express foreign antigens verysponses in chronic HCV carriers. (HEPATOLOGY 1997;25:
efficiently inside nonpermissive cells without spreading the470-477.)
infection.21,22 Based on these principles, we constructed a re-
combinant adenovirus containing core and E1 genes of HCV;
we then studied its ability to express these proteins in miceHepatitis C virus (HCV) is one of the major agents of
chronic hepatitis and liver diseases worldwide.1 Infection and human cells and to induce a cytotoxic immune response
in mice. As discussed in later paragraphs, our adenoviruswith HCV leads to chronic hepatitis in about 80% of cases.2-5
Chronic hepatitis C frequently evolves to cirrhosis, and a was very effective both in expressing HCV transgenes and
in stimulating specific CTL in mice against HCV antigens.significant proportion of patients with liver cirrhosis will de-
velop hepatocellular carcinoma (HCC).6 Treatment of chronic Fine mapping of CTL epitopes using overlapping peptides
allowed us to identify 6 peptides from core and one from E1hepatitis C with interferon alfa is effective in less than 50%
of patients, and a high proportion of those who respond to containing cytotoxic T cell determinants.
the treatment relapse soon after interferon withdrawal.7 It
MATERIALS AND METHODSis clear that the elaboration of a vaccine against HCV and
Mice. Female BALB/c mice (range, 4-6 weeks old) were purchased
from IFFA Credo (Barcelona, Spain). They were hosted in appro-
priated animal care facilities during the experimental period and
Abbreviations: RAd, recombinant adenovirus; HCV, hepatitis C virus; CTL, cytotoxic T were handled following the international guidelines required for ex-
lymphocyte. perimentation with animals.
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Cells and Viruses. Two hundred ninety-three cells23 (European col-University of Navarra, Pamplona, Spain; 2the Department of Medicine, University of Wales
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Service. P815 cells (ATCC TIB64) derive from a DBA/2 mouse mastocytoma
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and express H-2d class-I molecules. EL-4 cells (ATCC TIB39) deriveClıB nica Universitaria, Facultad de Medicina, Universidad de Navarra, C/Pio XII s.n., 31080
from a C57BL/6N mouse lymphoma and express H-2b class-I mole-Pamplona, Spain.
cules. Both EL-4 and P815 only express class-I but not class-II majorCopyright q 1997 by the American Association for the Study of Liver Diseases.
0270-9139/97/2502-0036$3.00/0 histocompatibility molecules. These two cell lines were cultured in
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Immunofluorescence. Immunofluorescence experiments in both
human and murine fibroblasts infected with RAdCMV-CE1,
RAdCMV-LacZ, or non-infected were carried out using standard
techniques. Briefly, fibroblasts were fixed with methanol, preincu-
bated with 3% bovine serum albumin in phosphate buffer saline to
block nonspecific binding and were then incubated with the primary
antibody, either human anti-HCV positive sera, a monoclonal anti-
core antibody (provided by Dr. E. Martinez, University of Navarra,
Pamplona, Spain), or a monoclonal anti-E1 antibody (anti-E1
mabIGH-201, provided by Dr. G. Maertens, Innogenetics, Ghent, Bel-
gium) at different dilutions (range, 1:20-1:100). Anti-human or anti-
mouse secondary antibodies fluorescein isothiocyanate conjugated
were added at 1:400 and 1:1,000 dilutions, respectively. After incuba-
tion, preparations were mounted and observed in an ultraviolet mi-
croscope. Extensive cell washes were performed between each incu-
bation period.
Peptide Synthesis. Peptides were synthesized by the solid phase
method of Merrifield,26 using the Fmoc alternative.27 Twenty-four
14-mer and thirty-six 15-mer (10 amino-acid overlap) peptides span-
ning the whole sequence of core and E1 proteins of HCV genotype
1b were synthesized using a multiple solid phase peptide synthe-
sizer28 and were used without further purification. Seven 10-mer (9
amino-acid overlap) peptides were also synthesized using the same
FIG. 1. Construction of RAdCMV-CE1. Plasmid pMVCE160, containing method to map the minimal epitope inside the 15-mer peptide 312-core and E1 sequences of HCV inside the CMV expression cassette and flanked
326.by adenoviral sequences, was transferred together with pJM17 into 293 cells
CTL Generation by Immunization With RAdCMV-CE1. Six-week old(an Ad5 DE1 permissive cell line). Recombination between homologous se-
female mice were immunized intraperitoneally with 108 pfu ofquences from both plasmids permitted the recovery of a new virus (RAdCMV-
CE1) with both HCV transgenes inserted into the genome. RAdCMV-CE1 virus in 500 mL of phosphate-buffered saline. Ten
days after immunization, spleens were removed and homogenized,
cells were cultured in vitro in 24-well plates at 3 1 106 cells/mL
in the presence of different peptide pools (Tables 1 and 2). A final
concentration of 5 mg/mL of each peptide, dissolved in RPMI-1640RPMI-1640 medium plus 10% fetal calf serum, antibiotics, and 5 1
medium supplemented with 10% fetal calf serum, antibiotics, and 51005 mol/L 2-mercaptoethanol at 377C and 5% CO2 and were used 1 1005 mol/L of 2-mercaptoethanol was used. Six days later, cytotoxicas target cells for cytotoxicity assays.
activity was measured.18Neo cells (kindly provided by Dr. Jay A. Berzofsky, Food and
51Cr Release Cytotoxic Assay. CTL activity was measured using aDrug Administration, Bethesda, MD) derive from BALB/c 3T3 fibro-
conventional cytotoxicity assay.29 Assays were done in triplicate atblasts and express H-2d molecules. This cell line was cultured in
different effectors to target cell ratios (as indicated in each experi-Dulbecco’s minimal essential medium with 10% fetal calf serum and
ment); the spontaneous release was in all cases below 25% of totalantibiotics at 377C and 5% CO2. release. A positive response was considered when the percentage ofPlasmids. Recombinant complementary DNA clones, generated
specific lysis against target cells incubated with one specific peptidefrom a chronic HCV carrier by polymerase chain reaction, were re-
exceeded the percentage of lysis obtained by calculating means /constructed into longer continuous sequences by ligation through
natural restriction sites. One clone, pK155, contains sequences repre-
senting a genotype 1b entire core and E1 regions and terminates
TABLE 1. Peptide Mixtures Corresponding to the Core Region ofwithin the middle of the E2 gene. This clone was initially modified
HCV Used for In Vitro Restimulation of BALB/c Mice Spleen Cellsusing synthetic oligonucleotides to provide a termination codon
Immunized With RAdCMV-CE1(TAA) and a novel XbaI site at the 3*terminus of the E1 gene. This
allowed the entire core and E1 regions to be inserted as an XbaI Aminoacid Position Aminoacid Sequence
fragment downstream of the cytomegalovirus major immediate early
promoter (CMV IEP) into the transient expression vector pMV100.22 1-14 MSTNPKPQRKTKRN
The CMV IEP/HCV core and E1 expression cassette was then excised 39-52 RRGPRLGVRATRKT
on a Hind III fragment and inserted into the adenovirus recombina- 53-66 SERSQPRGRRQPIP Pool 1
tion vector pMV60, essentially as described by Jacobs et al.21 to gen- 71-84 PEGRAWAQPGYPWP
erate pMVCE160. The integrity of pMVCE160 was confirmed by 85-98 LYGNEGMGWAGWLL
restriction endonuclease cleavage and nucleic acid sequence analysis
99-112 SPRGSRPSWGPTDPof the insert.
113-126 RRRSRNLGKVIDTLGeneration of Recombinant Adenoviruses. The recombinant Pool 2
169-182 LPGCSFSIFLLALLadenovirus (RAd) RAdCMV-CE1 (RAdCMV-CE1) was generated us-
178-191 LLALLSCLTIPASAing the technique of McGrory et al.24 As shown in Fig. 1, plasmids
pMVCE160 and pJM17 were cotransfected into 293 cells. pJM17 6-19 KPQRKTKRNTNLRP
contains the complete Ad type 5 d1309 genome modified to exceed 41-54 GPRLGVRATRKTSE
the adenovirus packaging limit. Homologous recombination between 57-70 QPRGRRQPIPKARQ Pool 3
the two plasmids results in the transgene being inserted into the Ad 76-89 WAQPGYPWPLYGNE
genome in place of its E1 gene region. This decrease in the size of 90-103 GMGWAGWLLSPRGS
the Ad5 genome enables the generation of RAdCMV-CE1 encoding
HCV core and E1. 132-145 DLMGYIPLVGAPLG
151-164 LAHGVRVLEDGVNYRAdCMV-CE1 was propagated on 293 cells and purified in a CsCl
Pool 4
173-186 SFSIFLLALLSCLTisopicnic banding step. The viral band was dialyzed against 0.01 mol/
11-24 TKRNTNLRPQDVKFL Tris, pH 8. At this stage, the virus was kept in aliquots at 0807C.
All transfections were carried out using the calcium phosphate
34-47 VYLLPRRGPRLGVRprecipitation method as described by F. Graham et al.25
46-59 VRATRKTSERSQPR Pool 5The construction of recombinant adenovirus RAdCMV-LacZ con-
109-122 PTDPRRRSRNLGKVtaining the LacZ reporter gene has already been described else-
where.22 Transduction of both mouse and human fibroblasts using 37-50 LPRRGPRLGVRATR
this construct was very efficient since at a relatively low multiplicity 48-61 ATRKTSERSQPRGR Pool 6
of infection (10) the expression of the reporter gene was observed in 165-178 ATGNLPGCSFSIFL
over 70% of the cells.
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TABLE 2. Peptide Mixtures Corresponding to the E1 Region of HCV combinant adenovirus containing core and E1 proteins from
Used for In Vitro Restimulation of BALB/c Mice Spleen Cells HCV (RAdCMV-CE1) were able to express the recombinant
Immunized With RAdCMV-CE1 proteins, we performed Western transfer analysis of cell ex-
tracts from mice (18Neo) and human fibroblasts (from skinAminoacid Position Aminoacid Sequence*
biopsies) infected with RAdCMV-CE1 using seropositive hu-
192-206 YEVRNVSGIYHVTNDA man sera as source of primary antibodies. A band sized at
207-221 CSNSSIVYETADMINA 22 kd corresponding to the core protein and several bands
222-236 HTPGCVPCVREGNSSA sized from 30 to 35 kd corresponding to E1 protein iso-Pool 1
237-251 RCWVALTPTLAAKDAA forms30,31 were detected (data not shown).252-266 SIPTATIRRHVDLLVA
To confirm that RAdCMV-CE1 express HCV core and E1267-281 GAAAFCSAMYVGDLCA
proteins in the infected cells, immunofluorescence experi-
282-296 GSVFLVSQLFTFSPRA ments using anti-HCV–positive human sera, a monoclonal
297-311 RHQTVQDCNCSIYPGA anti-core antibody, and a monoclonal anti-E1 antibody were
312-326 HVSGHRMAWDMMMNWA also performed. Figure 2 shows the indirect immunofluores-Pool 2
327-341 SPTAALVVSQLLRIPA cent staining of mouse and human fibroblasts, infected with342-356 QAVVDMVAGAHWGVLA
RAdCMV-CE1, with RAdCMV-LacZ, or noninfected, incu-357-371 AGLAYYSMVGNWAKVA
bated with human seropositive serum, monoclonal anti-core
197-211 VSGIYHVTNDCSNSSA antibody, or monoclonal anti-E1 antibody. As observed in the
212-226 IVYETADMIMHTPGCA figure, a dotted coarse granular pattern of specific staining
227-241 VPCVREGNSSRCWVAA was noted when the monoclonal anti-core antibody was usedPool 3
242-256 LTPTLAAKDASIPTAA as the primary antibody (Fig. 2D), while a diffuse punctuated257-271 TIRRHVDLLVGAAAFA
cytoplasmic pattern was found when using anti-E1 antibody272-286 CSAMYVGDLCGSVFLA
(Fig. 2E). A combination of both patterns was found when
287-301 VSQLFTFSPRRHQTVA human anti-HCV positive serum was employed, suggesting
302-316 QDCNCSIYPGHVSGHA the recognition of both core and E1 proteins by this serum
317-331 RMAWDMMMNWSPTAAA
Pool 4
332-346 LVVSQLLRIPQAVVDA
347-361 MVAGAHWGVLAGLAYA
362-376 YSMVGNWAKVLVVMLA
202-216 HVTNDCSNSSIVYETA
217-231 ADMIMHTPGCVPCVRA
232-246 EGNSSRCWVALTPTLA
Pool 5
247-261 AAKDASIPTATIRRHA
262-276 VDLLVGAAAFCSAMYA
277-291 VGDLCGSVFLVSQLFA
292-306 TFSPRRHQTVQDCNCA
307-321 SIYPGHVSGHRMAWDA
322-336 MMMNWSPTAALVVSQA
Pool 6
337-351 LLRIPQAVVDMVAGAA
352-366 HWGVLAGLAYYSMVGA
367-381 NWAKVLVVMLLFAGVA
* The underlined A was added for synthesis convenience.
2.6 SD (P .01) of the values from control wells containing unpulsed
target cells.
When peptides were used, target cells P815 (H-2d restricted) or
EL-4 (H-2b restricted) were radiolabelled with 50 mCi of Na251CrO4
per 106 cells for one hour at 377C, washed twice, and incubated with
5 mg/mL of the relevant peptide.
When recombinant adenoviruses were used to express proteins
inside target cells, these, 18Neo (H-2d restricted), were infected with
either RAdCMV-CE1 or RAdCMV-LacZ for 36 hours before the
assays, to allow gene expression. Subsequent radiolabeling of the
cells was carried out, as previously described.
Abrogation of the CTL Response by Anti-CD4 and Anti-CD8 Mono-
clonal Antibodies. L3T4 rat anti-mouse hybridomas GK1-5 (CD4 spe-
cific) and H35.17.2 (CD8 specific) (kindly provided by Dr. C. Leclerc,
Institute Pasteur, Paris, France) were used to obtain anti-CD4 and
anti-CD8 monoclonal antibodies. Ascitic fluid was obtained from
nude mice, was pristane primed, and was injected intraperitoneally
with 106 hybridoma cells. Antibodies were prepared by precipitation
with ammonium sulphate followed by dialysis against phosphate-
buffered saline. Protein concentration was assessed by optical den-
sity measurement at 280 nm. In the CTL response-blocking experi- FIG. 2. Indirect immunofluorescence of HCV proteins expressed by recom-
ments, the chromium release assay was carried out in the presence binant defective adenovirus in human or mouse fibroblasts. Human fibroblasts
of anti-CD4 or anti-CD8 antibodies (10 mg/mL of final concentration) (A-F) infected with RAdCMV-CE1 (A, D, E, and F), RAdCMV-LacZ (B), and
plus complement from rabbit serum (final dilution, 1:20). noninfected (C) were incubated with human anti-HCV positive serum (A, B,
C, and F), with a mouse monoclonal anti-core antibody (D) or with a mouse
monoclonal anti-E1 antibody (E). Mouse fibroblasts (G, H, and I) infected withRESULTS
RAdCMV-CE1 (G and H) or RAdCMV-LacZ (I) were incubated with human
Expression of HCV Proteins in Human Fibroblasts Using anti-HCV positive serum. Magnification was 1200 in A, B, C, G, and I; 1400
in D; and 11000 in E, F, and H.RAdCMV-CE1. To know whether the replication-deficient re-
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(Fig. 2A, 2F, 2G, and 2H). These experiments indicate a high
efficiency of expression of recombinant HCV proteins by our
adenoviral vector. The fine punctuate staining of the infected
cells using the anti-E1 antibody and the granular pattern
observed with anti-core suggest the association of these re-
combinant proteins with cell membranes, as previously de-
scribed.30 These two distinct immunofluorescence patterns
have also been observed by others.32,33
Induction of CTL in Mice Using RAdCMV-CE1. RAdCMV-
CE1 was used to immunize BALB/c mice in an attempt to
induce a CTL response against HCV structural proteins. The
mice were immunized by intraperitoneal route with 108 pfu
of virus; after 10 days their spleens were removed. In order
to assess CTL activity against core and E1, these spleen cells
were incubated in the presence of pools of overlapping syn-
thetic peptides (Tables 1 and 2) spanning the whole sequence
of these proteins. After six days in culture, CTL activity was
tested against P815 cells incubated with each specific pep- FIG. 4. Experiment to rule out that the observed cytotoxic T cell response
tide, using a chromium release assay. Figures 3A and 3B was not induced in vitro. Immunized [i] and non-immunized [ni] BALB/c mice
spleen cells were restimulated in vitro for six days with peptides from coreshow that the immunization of mice with the recombinant
(34-47, 39-52, 132-145, 165-178, and 173-186) and E1 (312-326). They wereresulted in a CTL response that was directed against P815
then tested against P815 cells sensitized with individual core and E1 peptides.target cells incubated with six core peptides [34-47, 37-50, Results show that only mice previously immunized with RAdCMV-CE1 display
39-52, 132-145, 165-178, and 173-186] and a single E1 pep- cytotoxic activity against the target cells.
tide [312-326]. The first three core peptides most probably
correspond to two determinants: one spanning residues 35-
44 (contained in peptide 34-47) already described by Cerny spanning residues 41-49 (contained in peptides 37-50 and 39-
52) as described by Koziel et al.35 in patients with chronicet al. in chronic HCV infected patients,34 and the other one
hepatitis C. Core peptides 132-145 and 173-186 have also
been found to function as CTL determinants in humans.18,34,36
These results indicate the importance of the highly conserved
core protein as a target for cytotoxic T cells and they also
illustrate the importance of mice studies to predict cytotoxic
epitopes in humans.37 While most CTL determinants that
were found in the core protein were previously described, the
E1 epitope encountered in this study was novel.
As observed in Fig. 3A, background cytolytic activity was
relatively high for those core peptides corresponding to pools
4 (peptides 11-24, 132-145, 151-164, and 173-186) and 6 (pep-
tides 37-50, 48-61, and 165-178). However the difference be-
tween specific lysis and background lysis defining positive
responses (2.6 SD of the mean of cytotoxicity values in wells
containing unpulsed target cells) was maintained in confir-
matory experiments for the different core peptides tested
(data not shown). This high background might be related to
the presence in the pool of peptides possessing T-helper cell
determinants able to activate interleukin-2 production thus
generating nonspecific CTL activity during in vitro restimu-
lation.38
We analyzed whether the observed cytotoxic T-cell re-
sponses against different epitopes from core and E1 were
indeed induced in vivo by the recombinant adenovirus and
not by the in vitro incubation of spleen cells with the corre-
sponding peptide. To this we compared the cytotoxic activity
of lymphocytes from immunized and nonimmunized mice,
stimulated in vitro with the peptides eliciting positive cyto-
toxic responses, against target cells sensitized with these
same peptides. Figure 4 shows that the cytotoxic activity of
cells from mice immunized with RAdCMV-CE1 was signifi-
cantly higher than that observed when using cells from non-
immunized mice, indicating the ability of RAdCMV-CE1 to
induce cytotoxic T cells in animals infected with this vector.FIG. 3. CTL activity (51Cr release assay) of spleen cells from BALB/c mice
immunized with recombinant adenovirus RAdCMV-CE1 against P815 target Characterization of CTL Response. As mentioned, most of
cells preincubated with overlapping synthetic peptides spanning HCV core (A) the epitopes we found in core had been previously described
and E1 (B) proteins. Before the assay splenocytes were restimulated in vitro and their minimal CTL epitopes identified,18,34,35,36 while thewith pools of peptides (Tables 1 and 2) as indicated in Materials and Methods.
E1 312-326 peptide was novel. We selected this peptide,For each peptide, a double cytotoxicity value is shown: the specific lysis ob-
tained when the peptide is added to target cells (j); and the background lysis which corresponds to a highly conserved motif among all HCV
of unpulsed target cells (h). A positive response was considered when the isolates, to further characterize the CTL response induced
percentage of specific lysis of target cells incubated with the peptide exceeded by our adenoviral recombinant.means { 2.6 SD (P  .01) of the values from the control wells containing
Several studies (e.g., references 39 and 40) have indicatedunpulsed target cells. Effector to target cell ratios used were: 50:1 for core
derived peptides and 16.6:1 for E1 peptides. *Positive cytotoxic responses. that the usual length of processed antigen, found complexed
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TABLE 3. Recognition of 10-mer Overlapping Peptides From 312-326
by the CTL Induced in BALB/c Mice With RAdCMV-CE1
% Lysis
Peptide* Ratio 50:1 Ratio 16:1
HVSGHRMAWDMMMNWA (312-326) 70 41
HVSGHRMAWA 30 18
VSGHRMAWDA 57 35
SGHRMAWDMA 50 35
GHRMAWDMMA 45 37
HRMAWDMMMA 31 24
RMAWDMMMNA 25 22
MAWDMMMNWA 26 17
None 22 13
* The underlined A was added for synthesis convenience.
FIG. 5. Recognition of endogenously synthesized antigens. 18 Neo cells
previously infected with RAdCMV-CE1, the control adenovirus RAdCMV-LacZ
or non-infected were used as targets in a chromium release assay, using immu-
nized BALB/c mice spleen cells which had been restimulated with peptide 312-
to class-I molecules on antigen presenting cells, is between 8 326. Effector to target cell ratio for this experiment was 25:1.
and 10 amino acids. Thus, to define the minimal CTL epitope
present in peptide 312-326, we synthesized the overlapping
10-mer peptides covering its entire sequence (Table 3). These
plement. CTL activity against P815 target cells incubatedpeptides were used to preincubate P815 target cells which
with peptide 312-326 was abrogated by anti-CD8 antibodieswere then assessed for their susceptibility to lysis by CTL
plus complement but not by the addition of anti-CD4 plusderived from immunized mice. Table 3 shows that the deter-
complement or by complement alone (Fig. 6A). This indicatesminant is present in decapeptides 2, 3, and 4, indicating that
that the CTL induced by immunization with RAdCMV-CE1the minimal epitope comprises the amino acid sequence
corresponds to cells with the phenotype CD40 CD8/.GHRMAWDM.
Experiments were also performed to map the major histo-The minimal determinant identified in Table 3 corresponds
compatibility complex-restriction of the CTL induced byto a highly conserved region of E1 among different geno-
immunization with RAdCMV-CE1. To this aim we comparedtypes.41 However, the region flanking the N-terminus of this
CTL-mediated lysis using class-I matched target cells fromdeterminant does vary between genotypes. To study the effect
an H-2d background (P815) and class-I mismatched cells fromof these amino acid changes on the CTL activity induced with
an H-2b background (EL-4). Both cell types were preincu-RAdCMV-CE1 expressing the sequence of genotype 1b, we
bated with peptide 312-326 and then analyzed in a cytotoxic-synthesized peptide 312-326 corresponding to HCV genotype
ity assay against lymphocytes from BALB/c mice (H-2d) im-1a and compared the recognition of P815 target cells preincu-
munized with RAdCMV-CE1. Figure 6B shows that onlybated with peptide sequences 312-326 from genotypes 1b and
class-I matched target cells were lysed (P815) indicating that1a. Table 4 shows that the amino acid mutations at positions
the CTL response to RAdCMV-CE1 was H-2d restricted.313 and 314 (which lay outside the minimal epitope) do not
To study the kinetics of the specific cytotoxic T-cell activityprevent the recognition of target cells by CTL.
generated by immunization with RAdCMV-CE1, further ex-We also investigated whether cytotoxic T cells from immu-
periments were performed in which mice were killed betweennized mice, restimulated in vitro with peptide 312-326, were
10 and 100 days, postintraperitoneal injection of the recombi-able to recognize not only target cells incubated with this
nant. We found that spleen cells isolated from mice at 10,peptide but also the determinant derived from the naturally
40, and 100 days postimmunization displayed similar cyto-processed viral protein presented on the membrane of cells
toxicity when incubated with target cells sensitized with pep-infected with RAdCMV-CE1. As controls we used 18Neo cells
tide 312-326 (data not shown). Because RAdCMV-CE1 is ainfected with a recombinant adenovirus expressing b-galac-
nonreplicating adenoviral vector, these findings indicate thattosidase (RAdCMV-LacZ) and noninfected cells. Figure 5
the primary CTL response induced upon a single immuniza-shows that 18Neo cells infected with RAdCMV-CE1, there-
tion can be sustained for at least 100 days.fore exhibiting native HCV E1 processed peptides complexed
to major histocompatibility complex class-I molecules, were
DISCUSSIONpredominantly recognized and lysed whereas the same cells
infected with the control virus or that were non-infected were Following infection with a virus, endogenously synthesized
not. viral proteins are processed to yield short peptides which
To further characterize the nature of the CTL response to bind to major histocompatibility complex class I molecules
RAdCMV-CE1, the phenotype of the induced lymphocytes for presentation on the cell membrane to CD8/ CTLs which,15
was analyzed by carrying out the cytotoxicity assay in the together with CD4/ helper T cells, are believed to play a
presence of either anti-CD4 or anti-CD8 antibodies plus com- critical role in the clearance of viral infections.11,14,42,43 Direct
delivery of fragments of DNA encoding viral proteins to the
cells can reproduce this same chain of events, leading to the
TABLE 4. Cross Recognition of Peptides From Genotype 1a and 1b by induction of a protective antiviral immunity.8,10,21,44-46
the CTL Induced With RAdCMV-CE1 Recombinant viruses constitute an efficient means for DNA
transfer to cells both in vivo and in vitro. When transgenes% Lysis
are placed in these vectors under the drive of a strong pro-
Peptide* Genotype Ratio 15:1 Ratio 5:1 moter such as cytomegalovirus immediate early promoter, as
in this study, it is possible to achieve a high level of expres-
HVSGHRMAWDMMMNWA 1a 60 29 sion of the recombinant proteins. Several reports8,10,44-46 have
-IT------------A 1b 48 26
shown that infection of animals with recombinant virusesNone 27 11
encoding transgenic viral proteins is able to induce protective
* The underlined A was added for synthesis convenience. immunity to the virus of interest in a number of systems.
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RAdCMV-CE1 was able to express HCV core and E1 proteins
both in mice and human cells, and that this vector induced
in mice a strong CTL response against different epitopes from
core (peptides 34-47, 37-50/39-52, 132-145, 165-178, and 173-
186) and E1(312-326).
Under the conditions of our immunization protocol (one
single injection of the vector) we were able to induce cellular
but not humoral immunity to HCV proteins. However it
should be mentioned that immunization with repeated injec-
tions of a recombinant defective adenovirus expressing HCV
structural proteins under the control of a Roux sarcoma a
promoter has succeeded in inducing humoral immunity to
HCV.49
One of the dominant cytotoxic T-cell epitopes that we have
found in core was encompassed by two overlapping peptides:
37-50 and 39-52. This cytotoxic T-cell determinant may corre-
spond to epitope 41-49, described by Koziel et al.,35 as recog-
nized by liver infiltrating lymphocytes from patients with
chronic HCV infection. Peptide 34-47 contains, based on pre-
dictions,50,42 a different epitope which has also been signaled
by Cerny et al.34 and by Battegay et al.36 as recognized by
peripheral blood lymphocytes in HLA-A2 positive chronic
hepatitis C patients. Of interest, two out of the other three
core determinants (peptides 132-145 and 173-186) had also
been described by Cerny et al.34 (both peptides), by Battegay
et al.,36 (peptide 173-186) and by Shirai et al.17,18 (peptide
132-145) as targets of CTL responses by peripheral blood
lymphocytes from HLA-A2 positive patients with chronic
hepatitis C. In addition to these observations, results from
our laboratory (Lasarte et al., unpublished observations, Jan-
uary 1996) using techniques based on competition for binding
to HLA-A2, have shown that peptide 165-178 also contains
an HLA-A2 binding motif. On the other hand, Shirai et al.17
have identified core peptide 133-142 as a cytotoxic T-cell de-
terminant in H-2d mice. Minimal epitopes of some of the
above described CTL determinants have been character-
ized.17,35 All of these results emphasize the importance of core
as a target of cytotoxic attack.
Although there are data indicating that cellular immunity
to core appears to play a role in the control of HCV infection,51
there is also evidence suggesting that immunity to envelope
proteins may contribute to viral clearance.52 Also we have
observed that patients with chronic hepatitis C who cleared
the virus after interferon therapy showed proliferative T cell
responses to peptides from E1, whereas there was little T-FIG. 6. Characterization of CTL induced by RAdCMV-CE1 against epitope
312-326 from E1. (A) Surface phenotype. The chromium release assay was cell recognition of these peptides in those which remained
carried out using P815 cells pulsed or unpulsed with peptide 312-326. The viremic after treatment.53 In the present study, we found that
assay was carried out under the conditions shown, in the presence of anti-CD4 while the cytotoxic activity induced by immunization withor anti-CD8 plus complement or complement alone. ( l ), p312-326;
RAdCMV-CE1 was directed against a diversity of epitopes in( j ), p312-326 / anti-CD4 / C1; ( m ), p312-326 / anti-CD8 / C1;
( ), p312-326 / C1; and ( ), unpulsed. (B) Major histocompatibility core, a single CTL epitope was found in E1. While most of
class I restriction of induced CTL was assessed using P815 (H-2d) or EL-4 (H- the cytotoxic T-cell determinants found in core had been pre-
2b) target cells pulsed with peptide 312-326. This figure shows that only class- viously described, the determinant encountered in E1 (pep-I matched target cells (P815) were lysed, indicating that the CTL response to
tide 312-326) was novel. This peptide was of interest sinceRAdCMV-CE1 was H-2d restricted. ( l ), P185; and ( ), EL-4.
in a previous study in patients with chronic hepatitis C, we
found that it also contains a helper T-cell determinant.53 In
fact the immunization of mice with this peptide induced aIt is not surprising, therefore, that this strategy has been
considered in the development of vaccines against a diversity specific CTL response of similar intensity as that elicited
with RAdCM1V-CE1 (Lasarte et al., unpublished observa-of viral agents.45,47,48 Because of the safety for humans of
disabled recombinant viral vectors,20 we used a replication- tions, March 1995). Moreover, the minimal CTL epitope of
this determinant (peptide GHRMAWDM) corresponds to adeficient adenoviral construct in order to express HCV pro-
teins in vivo and to induce a cytotoxic T cell response against highly conserved region among all HCV isolates, which in-
creases its value as one possible candidate for immunogen inthese antigens. Our immunofluorescence studies show the
ability of adenoviral vectors to express recombinant HCV pro- vaccine designs.
Further characterization of the response to this determi-teins at high levels and in a manner that is readily recognized
by antibodies elicited during natural infection. nant disclosed that the cytotoxic activity was mediated by
CD8/ T lymphocytes, was H-2d restricted, and was long last-Shirai et al.17 have reported that the administration of a
recombinant vaccinia virus expressing HCV core protein to ing. In this respect it is worth noting that one of the advan-
tages of using recombinant defective adenoviruses is thatmice resulted in the generation of a CTL response against a
conserved epitope of this protein. In the present work, we they permit a relatively long duration of the expression of the
recombinant proteins after a single injection of the vector.44 Itshow that the replication-deficient recombinant adenovirus
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